Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zhengye Biotechnology (Nasdaq: ZYBT) reported lower revenue but a narrower net loss for the six months ended June 30, 2026. Unaudited revenue fell 18.3% to RMB50.9 million, with declines across swine, poultry and other vaccines. Gross profit decreased to RMB16.7 million from RMB19.4 million, while gross margin rose to 32.9% from 31.1%.
Operating expenses fell 22.2% to RMB37.6 million, and operating loss narrowed 27.9% to RMB20.8 million. Net loss narrowed to RMB22.2 million from RMB25.6 million; basic and diluted loss per share improved to RMB0.40 from RMB0.46. Operating cash use increased to RMB16.8 million from RMB14.0 million. Cash fell to RMB31.9 million at June 30 from RMB50.3 million at December 31, 2025. The company aims to develop cat and dog vaccines and explore additional markets in Africa, Central Asia and West Asia.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFirst-half 2026 net loss narrowed to RMB22.2 million from RMB25.6 million a year earlier.
- Moderate pointFirst-half 2026 operating loss narrowed 27.9% to RMB20.8 million.
- Moderate pointFirst-half 2026 gross margin increased to 32.9% from 31.1% a year earlier.
- Minor pointOther-vaccine gross margin improved to 0.4% in first-half 2026 from negative 20.8% a year earlier.
- Minor pointPoultry-vaccine gross margin improved to negative 2.9% in first-half 2026 from negative 3.8% a year earlier.
11 minor points
- Minor pointFirst-half 2026 cost of revenue decreased 20.4% to RMB34.2 million.
- Minor pointFirst-half 2026 sales and marketing expenses fell to RMB18.6 million from RMB23.2 million a year earlier.
- Minor pointFirst-half 2026 administrative expenses decreased to RMB13.7 million from RMB16.8 million a year earlier.
- Minor pointFirst-half 2026 research and development expenses declined to RMB4.8 million from RMB9.0 million a year earlier.
- Minor pointFirst-half 2026 basic and diluted loss per share narrowed to RMB0.40 from RMB0.46 a year earlier.
- Minor pointFirst-half 2026 interest expense decreased to RMB1.565 million from RMB1.752 million a year earlier.
- Minor pointFirst-half 2026 foreign-exchange result improved to a RMB627,000 gain from a RMB1.421 million loss a year earlier.
- Minor pointFirst-half 2026 government subsidies rose to RMB893,000 from RMB502,000 a year earlier.
- Minor pointLong-term loans declined to RMB8.5 million at June 30, 2026, from RMB8.85 million at year-end 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Household-animal vaccine expansion remains a company aim, including developing cat and dog vaccines.
- Minor point. Forward-looking: it has not happened yet and may not happen.International expansion plans include exploring additional opportunities in Africa, Central Asia and West Asia.
Negative
- Moderate pointFirst-half 2026 revenue fell 18.3% to RMB50.9 million from RMB62.3 million a year earlier.
- Moderate pointFirst-half 2026 gross profit declined to RMB16.7 million from RMB19.4 million a year earlier.
- Moderate pointCash declined to RMB31.9 million at June 30, 2026, from RMB50.3 million at year-end 2025.
- Moderate pointFirst-half 2026 operating cash use increased to RMB16.8 million from RMB14.0 million a year earlier.
- Moderate pointFirst-half 2026 financing cash inflow decreased to RMB4.6 million from RMB42.3 million a year earlier.
10 minor points
- Minor pointFirst-half 2026 swine-vaccine revenue fell to RMB38.2 million from RMB46.7 million amid customer cost-cutting.
- Minor pointFirst-half 2026 poultry-vaccine revenue declined to RMB6.5 million from RMB7.0 million amid weak demand.
- Minor pointFirst-half 2026 other-vaccine revenue decreased to RMB6.2 million from RMB8.6 million amid lower customer demand.
- Minor pointSwine-vaccine gross margin decreased to 44.3% in first-half 2026 from 45.9% a year earlier.
- Minor pointFirst-half 2026 investing cash use increased to RMB5.7 million from RMB0.7 million a year earlier.
- Minor pointShort-term loans rose to RMB69.374 million at June 30, 2026, from RMB65.1 million at year-end 2025.
- Minor pointFirst-half 2026 credit losses were a RMB470,000 provision, versus a RMB719,000 reversal a year earlier.
- Minor pointFirst-half 2026 securities and derivatives recorded RMB1.326 million unrealized losses, versus RMB588,000 gains a year earlier.
- Minor pointDerivative liabilities reached RMB1.05 million at June 30, 2026, versus none at year-end 2025.
- Minor pointTotal equity fell to RMB283.412 million at June 30, 2026, from RMB306.715 million at year-end 2025.
Key Figures
- Net revenue
- RMB50.9 million (US$7.5 million), down 18.3%
- Six months ended June 30, 2026, versus the same period last year
- Gross profit margin
- 32.9%, up 1.8 percentage points from 31.1%
- Six months ended June 30, 2026, year over year
- Operating expenses
- RMB37.6 million, down 22.2%
- Six months ended June 30, 2026, year over year
- Operating loss
- Narrowed 27.9%
- Six months ended June 30, 2026, year over year
- Net loss
- RMB22.2 million (US$3.3 million), down 13.3%
- Six months ended June 30, 2026, versus RMB25.6 million in the same period last year
- Loss per share
- RMB0.40 (US$0.06), versus RMB0.46
- Basic and diluted, six months ended June 30, 2026, versus the same period last year
- Cash
- RMB31.9 million (US$4.7 million), versus RMB50.3 million
- As of June 30, 2026, versus December 31, 2025
- Net cash used in operating activities
- RMB16.8 million (US$2.5 million), versus RMB14.0 million
- Six months ended June 30, 2026, versus the same period last year
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "During the first half of fiscal year 2026, we continued to enhance profitability through disciplined cost management and operational efficiency. Despite the decline in net revenue and gross profit, we are encouraged by the improvement in our gross profit margin to
Mr. Aiden Han, co-chief executive officer of Zhengye, added, "We remain focused on advancing our long-term growth strategy through the development of high-demand vaccines and expansion into new markets. Building on our existing product development initiatives, we aim to further expand our presence in the household animal vaccine industry, including through the development of vaccines for cats and dogs. On the international front, with our products already exported to
First Six Months of Fiscal Year 2026 Financial Summary
- Net revenue was
RMB50.9 million (US ) for the six months ended June 30, 2026, compared to$7.5 million RMB62.3 million for the same period last year. - Gross profit was
RMB16.7 million (US ) for the six months ended June 30, 2026, compared to$2.5 million RMB19.4 million for the same period last year. - Gross profit margin was
32.9% for the six months ended June 30, 2026, an increase of 1.8 percentage points from31.1% for the same period last year. - Net loss was
RMB22.2 million (US ) for the six months ended June 30, 2026, compared to$3.3 million RMB25.6 million for the same period last year. - Basic and diluted loss per share was
RMB0.40 (US ) for the six months ended June 30, 2026, compared to$0.06 RMB0.46 for the same period last year.
First Six Months of Fiscal Year 2026 Financial Results
Net Revenue
Net revenue was
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the six months ended June 30, (Unaudited) |
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025 |
|
|
2026 |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except for percentages) |
|||||||||||||||||
|
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RMB |
|
|
% |
|
|
RMB |
|
|
US$ |
|
|
% |
|||||
|
Swine vaccines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46,706 |
|
|
|
74.9 |
|
|
|
38,202 |
|
|
|
5,630 |
|
|
|
75.0 |
|
Poultry vaccines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,015 |
|
|
|
11.3 |
|
|
|
6,496 |
|
|
|
957 |
|
|
|
12.8 |
|
Other vaccines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,607 |
|
|
|
13.8 |
|
|
|
6,249 |
|
|
|
922 |
|
|
|
12.2 |
|
Total revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62,328 |
|
|
|
100 |
|
|
|
50,947 |
|
|
|
7,509 |
|
|
|
100 |
- Revenue from sales of swine vaccines was
RMB38.2 million (US ) for the six months ended June 30, 2026, decreased from$5.6 million RMB46.7 million for the same period last year. Amid the broader industry environment, cost-cutting requirements from key customers resulted in lower sales volume. - Revenue from sales of poultry vaccines was
RMB6.5 million (US ) for the six months ended June 30, 2026, decreased from$1.0 million RMB7.0 million for the same period last year. This decline was primarily due to lower sales volume amid weak market demand in the broader industry environment. - Revenue from sales of other vaccines was
RMB6.2 million (US ) for the six months ended June 30, 2026, decreased from$0.9 million RMB8.6 million for the same period last year. Lower demand from key customers resulted in reduced sales volume.
Cost of Revenue
Cost of revenue was
Gross Profit
Gross profit was
Gross profit margin was
Operating Expenses
Total operating expenses were
- Sales and marketing expenses were
RMB18.6 million (US ) for the six months ended June 30, 2026, decreased from$2.7 million RMB23.2 million for the same period last year. The decrease in sales and marketing expenses mainly resulted from a decrease in payroll for sales staff and travel expenses. - General and administrative expenses were
RMB13.7 million (US ) for the six months ended June 30, 2026, decreased from$2.0 million RMB16.8 million for the same period last year. The decrease in administrative expenses was attributed to the decrease in employee compensation, professional service fees and travel expenses. The decrease in professional service fees was mainly because the Company incurred such fees in connection with the preparation for the Company's initial public offering for the six months ended June 30, 2025, while no such fees were incurred for the six months ended June 30, 2026. - Research and development expenses were
RMB4.8 million (US ) for the six months ended June 30, 2026, decreased from$0.7 million RMB9.0 million for the same period last year. The decrease in research and development expenses mainly resulted from a decrease in development material expenses and the absence of one-time bonuses paid to research and development personnel in connection with the Company's initial public offering in the current period.
Net Loss
Net loss was
Basic and Diluted Loss per Share
Basic and diluted loss per share was
Financial Condition
As of June 30, 2026, the Company had cash of
Net cash used in operating activities was
Net cash used in investing activities was
Net cash provided by financing activities was
Exchange Rate Information
This announcement contains translations of certain foreign currency amounts into
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company's operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity's products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt as of the date of this press release. The operating entity has three veterinary vaccine production floors (including 13 vaccine production lines), one quality examination center, and one animal facility for vaccine development, all operating in accordance with Good Manufacturing Practices for Veterinary Drugs issued by the Ministry of Agriculture and Rural Affairs of the PRC. For more information, please visit the Company's website: http://ir.jlzybio.com.
Forward-Looking Statements
This announcement contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the United States Securities and Exchange Commission.
For more information, please contact:
Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
|
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED |
||||||||||||
|
|
||||||||||||
|
|
|
As of |
|
|||||||||
|
|
|
December 31, |
|
|
June 30, |
|
||||||
|
|
|
RMB |
|
|
RMB |
|
|
US$ |
|
|||
|
ASSETS |
|
|
|
|
|
|
|
|
|
|||
|
Current assets: |
|
|
|
|
|
|
|
|
|
|||
|
Cash |
|
|
50,332 |
|
|
|
31,884 |
|
|
|
4,699 |
|
|
Restricted cash |
|
|
2 |
|
|
|
2 |
|
|
|
- |
|
|
Short-term investments |
|
|
1,560 |
|
|
|
1,284 |
|
|
|
189 |
|
|
Notes receivable, net |
|
|
- |
|
|
|
467 |
|
|
|
69 |
|
|
Accounts receivable, net |
|
|
18,485 |
|
|
|
24,865 |
|
|
|
3,665 |
|
|
Advance to suppliers |
|
|
2,208 |
|
|
|
1,233 |
|
|
|
182 |
|
|
Advance to suppliers-a related party |
|
|
- |
|
|
|
16 |
|
|
|
2 |
|
|
Inventories, net |
|
|
39,166 |
|
|
|
40,339 |
|
|
|
5,945 |
|
|
Prepayments and other current assets, net |
|
|
25,667 |
|
|
|
24,808 |
|
|
|
3,656 |
|
|
Total current assets |
|
|
137,420 |
|
|
|
124,898 |
|
|
|
18,407 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net |
|
|
236,812 |
|
|
|
226,431 |
|
|
|
33,372 |
|
|
Land use rights, net |
|
|
7,673 |
|
|
|
7,544 |
|
|
|
1,112 |
|
|
Intangible assets, net |
|
|
47,084 |
|
|
|
50,766 |
|
|
|
7,482 |
|
|
Right-of-use assets, net |
|
|
469 |
|
|
|
412 |
|
|
|
61 |
|
|
Long-term prepayments |
|
|
7,014 |
|
|
|
1,935 |
|
|
|
285 |
|
|
Total non-current assets |
|
|
299,052 |
|
|
|
287,088 |
|
|
|
42,312 |
|
|
Total assets |
|
|
436,472 |
|
|
|
411,986 |
|
|
|
60,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term loans |
|
|
65,100 |
|
|
|
69,374 |
|
|
|
10,224 |
|
|
Current maturities of long-term loans |
|
|
700 |
|
|
|
700 |
|
|
|
103 |
|
|
Derivative liabilities |
|
|
- |
|
|
|
1,050 |
|
|
|
155 |
|
|
Operating lease liabilities-current |
|
|
106 |
|
|
|
25 |
|
|
|
4 |
|
|
Accounts payable |
|
|
44,010 |
|
|
|
38,878 |
|
|
|
5,728 |
|
|
Contract liabilities |
|
|
4,752 |
|
|
|
3,405 |
|
|
|
502 |
|
|
Taxes payable |
|
|
2,345 |
|
|
|
2,774 |
|
|
|
409 |
|
|
Accrued expenses and other liabilities |
|
|
3,463 |
|
|
|
3,572 |
|
|
|
527 |
|
|
Total current liabilities |
|
|
120,476 |
|
|
|
119,778 |
|
|
|
17,652 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term loans |
|
|
8,850 |
|
|
|
8,500 |
|
|
|
1,253 |
|
|
Operating lease liabilities-non-current |
|
|
327 |
|
|
|
296 |
|
|
|
44 |
|
|
Deferred tax liabilities |
|
|
104 |
|
|
|
- |
|
|
|
- |
|
|
Total non-current liabilities |
|
|
9,281 |
|
|
|
8,796 |
|
|
|
1,297 |
|
|
Total liabilities |
|
|
129,757 |
|
|
|
128,574 |
|
|
|
18,949 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' equity: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Class A ordinary shares ( |
|
|
1 |
|
|
|
1 |
|
|
|
- |
|
|
Class B ordinary shares ( |
|
|
7 |
|
|
|
7 |
|
|
|
1 |
|
|
Additional paid-in capital |
|
|
240,752 |
|
|
|
240,752 |
|
|
|
35,482 |
|
|
Statutory reserves |
|
|
32,647 |
|
|
|
32,647 |
|
|
|
4,812 |
|
|
Retained deficit |
|
|
(21,633) |
|
|
|
(40,549) |
|
|
|
(5,976) |
|
|
Accumulated other comprehensive income |
|
|
(1,926) |
|
|
|
(3,066) |
|
|
|
(452) |
|
|
Total Zhengye Biotechnology Holding Limited's shareholders' equity |
|
|
249,848 |
|
|
|
229,792 |
|
|
|
33,867 |
|
|
Noncontrolling interests |
|
|
56,867 |
|
|
|
53,620 |
|
|
|
7,903 |
|
|
Total equity |
|
|
306,715 |
|
|
|
283,412 |
|
|
|
41,770 |
|
|
Total liabilities and equity |
|
|
436,472 |
|
|
|
411,986 |
|
|
|
60,719 |
|
|
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED |
||||||||||||
|
|
||||||||||||
|
|
|
For the six months ended June 30, |
|
|||||||||
|
|
|
2025 |
|
|
2026 |
|
||||||
|
|
|
RMB |
|
|
RMB |
|
|
USD |
|
|||
|
Net revenues |
|
|
62,328 |
|
|
|
50,947 |
|
|
|
7,509 |
|
|
Cost of revenues |
|
|
(42,944) |
|
|
|
(34,198) |
|
|
|
(5,040) |
|
|
Gross profit |
|
|
19,384 |
|
|
|
16,749 |
|
|
|
2,469 |
|
|
Sales and marketing expenses |
|
|
(23,243) |
|
|
|
(18,629) |
|
|
|
(2,746) |
|
|
General and administrative expenses |
|
|
(16,770) |
|
|
|
(13,703) |
|
|
|
(2,020) |
|
|
Research and development expenses |
|
|
(8,969) |
|
|
|
(4,770) |
|
|
|
(703) |
|
|
Reversal of (provision for) credit losses |
|
|
719 |
|
|
|
(470) |
|
|
|
(69) |
|
|
Total operating expenses |
|
|
(48,263) |
|
|
|
(37,572) |
|
|
|
(5,538) |
|
|
Operating loss |
|
|
(28,879) |
|
|
|
(20,823) |
|
|
|
(3,069) |
|
|
Other income (expenses): |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
72 |
|
|
|
11 |
|
|
|
2 |
|
|
Interest expense |
|
|
(1,752) |
|
|
|
(1,565) |
|
|
|
(231) |
|
|
Unrealized gains (losses) on marketable equity securities and derivative |
|
|
588 |
|
|
|
(1,326) |
|
|
|
(195) |
|
|
Unrealized foreign exchange gain (loss) |
|
|
(1,421) |
|
|
|
627 |
|
|
|
92 |
|
|
Government subsidy |
|
|
502 |
|
|
|
893 |
|
|
|
132 |
|
|
Other expenses |
|
|
- |
|
|
|
(79) |
|
|
|
(12) |
|
|
Total other expenses, net |
|
|
(2,011) |
|
|
|
(1,439) |
|
|
|
(212) |
|
|
Loss before income taxes |
|
|
(30,890) |
|
|
|
(22,262) |
|
|
|
(3,281) |
|
|
Income tax benefits |
|
|
5,340 |
|
|
|
99 |
|
|
|
14 |
|
|
Net loss |
|
|
(25,550) |
|
|
|
(22,163) |
|
|
|
(3,267) |
|
|
Net loss attributable to noncontrolling interests |
|
|
3,882 |
|
|
|
3,247 |
|
|
|
479 |
|
|
Net loss attributable to the Zhengye Biotechnology Holding Limited's |
|
|
(21,668) |
|
|
|
(18,916) |
|
|
|
(2,788) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
(25,550) |
|
|
|
(22,163) |
|
|
|
(3,267) |
|
|
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
|
(969) |
|
|
|
(1,140) |
|
|
|
(168) |
|
|
Total comprehensive loss |
|
|
(26,519) |
|
|
|
(23,303) |
|
|
|
(3,435) |
|
|
Total comprehensive loss attributable to non-controlling interest |
|
|
3,882 |
|
|
|
3,247 |
|
|
|
479 |
|
|
Total comprehensive loss attributable to the Zhengye Biotechnology |
|
|
(22,637) |
|
|
|
(20,056) |
|
|
|
(2,956) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
-Basic and diluted – Class A Ordinary shares |
|
|
(0.46) |
|
|
|
(0.40) |
|
|
|
(0.06) |
|
|
-Basic and diluted – Class B Ordinary shares |
|
|
(0.46) |
|
|
|
(0.40) |
|
|
|
(0.06) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding used in calculating basic and |
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares – basic and diluted |
|
|
47,316,793 |
|
|
|
47,391,376 |
|
|
|
47,391,376 |
|
|
Basic and diluted – Class A Ordinary shares |
|
|
7,316,793 |
|
|
|
7,391,376 |
|
|
|
7,391,376 |
|
|
Basic and diluted – Class B Ordinary shares |
|
|
40,000,000 |
|
|
|
40,000,000 |
|
|
|
40,000,000 |
|
|
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED |
||||||||||||
|
|
||||||||||||
|
|
|
For the six months ended June 30, |
|
|||||||||
|
|
|
2025 |
|
|
2026 |
|
||||||
|
|
|
RMB |
|
|
RMB |
|
|
US$ |
|
|||
|
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|||
|
Net loss |
|
|
(25,550) |
|
|
|
(22,163) |
|
|
|
(3,267) |
|
|
Adjustments to reconcile net loss to net cash provided by operating |
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
12,251 |
|
|
|
14,021 |
|
|
|
2,067 |
|
|
Amortization of operating lease right-of-use assets |
|
|
- |
|
|
|
52 |
|
|
|
8 |
|
|
Provision for (reversal of) credit losses |
|
|
(719) |
|
|
|
470 |
|
|
|
69 |
|
|
Impairment for inventory |
|
|
4,115 |
|
|
|
8,444 |
|
|
|
1,244 |
|
|
Deferred tax benefits |
|
|
(5,340) |
|
|
|
(104) |
|
|
|
(15) |
|
|
Unrealized (gains) losses on marketable equity securities and derivative |
|
|
(588) |
|
|
|
1,326 |
|
|
|
195 |
|
|
Unrealized foreign exchange (gain) loss |
|
|
1,421 |
|
|
|
(627) |
|
|
|
(92) |
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes receivable |
|
|
(99) |
|
|
|
(470) |
|
|
|
(69) |
|
|
Accounts receivable |
|
|
23,336 |
|
|
|
(6,874) |
|
|
|
(1,013) |
|
|
Advance to suppliers |
|
|
(1,572) |
|
|
|
975 |
|
|
|
144 |
|
|
Advance to suppliers-a related party |
|
|
- |
|
|
|
(16) |
|
|
|
(2) |
|
|
Inventories |
|
|
554 |
|
|
|
(9,616) |
|
|
|
(1,417) |
|
|
Prepayments and other current assets |
|
|
(23,379) |
|
|
|
189 |
|
|
|
28 |
|
|
Other receivable -a related party |
|
|
738 |
|
|
|
- |
|
|
|
- |
|
|
Operating lease liabilities |
|
|
- |
|
|
|
(107) |
|
|
|
(16) |
|
|
Accounts payable |
|
|
(1,513) |
|
|
|
(1,505) |
|
|
|
(223) |
|
|
Contract liabilities |
|
|
1,516 |
|
|
|
(1,347) |
|
|
|
(199) |
|
|
Taxes payable |
|
|
115 |
|
|
|
429 |
|
|
|
63 |
|
|
Accrued expenses and other liabilities |
|
|
746 |
|
|
|
110 |
|
|
|
17 |
|
|
Net cash used in operating activities |
|
|
(13,968) |
|
|
|
(16,813) |
|
|
|
(2,478) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loans to a related party |
|
|
(7,000) |
|
|
|
- |
|
|
|
- |
|
|
Loan repayment from a related party |
|
|
7,000 |
|
|
|
- |
|
|
|
- |
|
|
Purchase of property, plant and equipment |
|
|
(255) |
|
|
|
(3,377) |
|
|
|
(498) |
|
|
Prepayment for purchase of intangible assets |
|
|
(409) |
|
|
|
(2,360) |
|
|
|
(348) |
|
|
Net cash used in investing activities |
|
|
(664) |
|
|
|
(5,737) |
|
|
|
(846) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from loans |
|
|
41,910 |
|
|
|
46,810 |
|
|
|
6,899 |
|
|
Repayment of loans |
|
|
(44,000) |
|
|
|
(42,260) |
|
|
|
(6,228) |
|
|
Repayment to a related party |
|
|
(146) |
|
|
|
- |
|
|
|
- |
|
|
Proceeds from initial public offering |
|
|
43,081 |
|
|
|
- |
|
|
|
- |
|
|
Shareholder contribution |
|
|
1,470 |
|
|
|
- |
|
|
|
- |
|
|
Net cash provided by financing activities |
|
|
42,315 |
|
|
|
4,550 |
|
|
|
671 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and restricted cash |
|
|
(680) |
|
|
|
(448) |
|
|
|
(66) |
|
|
Net increase (decrease) in cash and restricted cash |
|
|
27,003 |
|
|
|
(18,448) |
|
|
|
(2,719) |
|
|
Cash and restricted cash at beginning of period |
|
|
18,606 |
|
|
|
50,334 |
|
|
|
7,418 |
|
|
Cash and restricted cash at end of period |
|
|
45,609 |
|
|
|
31,886 |
|
|
|
4,699 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest |
|
|
1,700 |
|
|
|
1,564 |
|
|
|
231 |
|
|
Income taxes |
|
|
- |
|
|
|
5 |
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NON-CASH INVESTING AND FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities assumed in connection with purchase of property, plant and |
|
|
1,521 |
|
|
|
151 |
|
|
|
22 |
|
|
Derecognition of right-of-use asset and lease liability due to operating |
|
|
- |
|
|
|
5 |
|
|
|
1 |
|
|
Reclassification of deferred initial public offering cost into additional |
|
|
8,663 |
|
|
|
- |
|
|
|
- |
|
View original content:https://www.prnewswire.com/news-releases/zhengye-biotechnology-holding-limited-announces-financial-results-for-the-first-six-months-of-fiscal-year-2026-302936788.html
SOURCE Zhengye Biotechnology Holding Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Zhengye Biotechnology's first-half 2026 revenue and net loss?
Zhengye reported revenue of RMB50.9 million and a net loss of RMB22.2 million for the six months ended June 30, 2026. Revenue decreased 18.3% year over year, while net loss narrowed from RMB25.6 million. Basic and diluted loss per share was RMB0.40, compared with RMB0.46.
Why did Zhengye Biotechnology's other-vaccine gross margin improve in first-half 2026?
Other-vaccine gross margin improved mainly because sales volume of sheep vaccines, which carry relatively high unit costs and fixed production costs, decreased amid weak demand. The segment's margin increased to 0.4% for the six months ended June 30, 2026, from negative 20.8% a year earlier.
What drove Zhengye Biotechnology's expense reductions in first-half 2026?
Lower employee-related and travel costs helped reduce sales and administrative expenses, while research spending fell with lower development-material expenses and no repeat of IPO-related one-time bonuses. Administrative expenses also benefited from the absence of professional service fees incurred for IPO preparation in the comparable 2025 period. Research and development expenses declined to RMB4.8 million from RMB9.0 million.